Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mapping MHC-resident transplantation determinants.

Mari Malkki1, Ted A Gooley, Mary M Horowitz

  • 1The Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|July 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended HLA Haplotypes and Transplant Survival.

Blood·2026
Same author

Umbilical cord blood transplantation in children with Diamond-Blackfan anemia.

Bone marrow transplantation·2026
Same author

Nomenclature for Factors of the HLA System, 2026.

HLA·2026
Same author

Subsequent Neoplasms After Umbilical Cord Blood Transplantation in the Japanese and European Populations.

Transplantation and cellular therapy·2026
Same author

Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation.

Transplantation and cellular therapy·2025

Major histocompatibility complex (MHC) microsatellite markers, beyond HLA genes, influence outcomes in hematopoietic cell transplantation (HCT). Mismatching specific microsatellites impacts risks of death and acute graft-versus-host disease (GVHD).

Area of Science:

  • Immunogenetics
  • Transplantation immunology
  • Human genetics

Background:

  • Graft-versus-host disease (GVHD) is a significant complication following HLA-identical unrelated hematopoietic cell transplantation (HCT), increasing morbidity and mortality.
  • The role of genetic variations within the major histocompatibility complex (MHC) beyond classical human leukocyte antigen (HLA) genes in HCT outcomes is not fully understood.

Purpose of the Study:

  • To investigate the hypothesis that MHC encodes functional genetic variations impacting HCT outcomes, independent of classical HLA matching.
  • To assess the association between donor-recipient mismatching of MHC microsatellite (Msat) markers and risks of mortality and acute GVHD in HCT.

Main Methods:

  • Analysis of 819 HCT recipients and their HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors.

Related Experiment Videos

  • Measurement of risks associated with donor-recipient mismatching for specific MHC microsatellite markers (D6S105, D6S2787, D6S2749, D6S2811, D6S265).

    • Main Results:

    • Mismatching for MHC microsatellite markers D6S105, D6S2787, and D6S2749 was associated with an increased risk of death (P=.03, P=.02, P=.007, respectively).
    • Mismatching for MHC microsatellite marker D6S2811 was associated with a decreased risk of death (P=.03).
    • Mismatching for MHC microsatellite marker D6S265 was associated with a decreased risk of grades III-IV acute GVHD (P=.04).

    Conclusions:

    • Microsatellite markers within the MHC may represent important genetic variations influencing HCT transplant outcomes.
    • These findings suggest that MHC microsatellites could be valuable for mapping clinically relevant genetic variation in HCT, potentially improving patient stratification and risk assessment.